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Gaucher’s disease (GD) is caused by mutations
that compromise b-glucocerebrosidase (GCase)
folding in the endoplasmic reticulum (ER), lead-
ing to excessive degradation instead of trafficking,
which results in insufficient lysosomal function.
We hypothesized that ER GCase interacting pro-
teins play critical roles in making quality control
decisions, i.e., facilitating ER-associated degrada-
tion (ERAD) instead of folding and trafficking.
Utilizing GCase immunoprecipitation followed by
mass-spectrometry-based proteomics, we identified
endogenous HeLa cell GCase protein interactors,
including ERdj3, an ER resident Hsp40 not previ-
ously established to interact with GCase. Depleting
ERdj3 reduced the rate of mutant GCase degrada-
tion in patient-derived fibroblasts, while increasing
folding, trafficking, and function by directing
GCase to the profolding ER calnexin pathway. In-
hibiting ERdj3-mediated mutant GCase degradation
while simultaneously enhancing calnexin-asso-
ciated folding, by way of a diltiazem-mediated in-
crease in ER Ca2+ levels, yields a synergistic rescue
of L444P GCase lysosomal function. Our findings
suggest a combination therapeutic strategy for
ameliorating GD.
INTRODUCTION
The maintenance of the proteome in each subcellular compart-
ment by its protein homeostasis, or proteostasis, network is
crucial for normal organismal physiology (Balch et al., 2008;
Ong and Kelly, 2011; Powers et al., 2009). One-third of the
eukaryotic proteome has to be properly folded in the endo-
plasmic reticulum (ER) before these proteins can be trafficked
to their destination environment, including outside of the cell,
or in the case of lysosomal enzymes, trafficked to the lyso-
some (Brodsky and Skach, 2011; Futerman and van Meer,
2004; Reczek et al., 2007; Zhao and Grabowski, 2002). In-Chemistry & Biology 21, 96herited mutations in genes encoding lysosomal enzymes often
lead to destabilized enzymes, resulting in excessive ER mutant
enzyme misfolding and ER-associated degradation (ERAD)
(Brodsky and Skach, 2011; Hebert et al., 2010; Vembar and
Brodsky, 2008). Excessive degradation can lead to loss of
activity of a particular enzyme in the lysosome, resulting
in substrate accumulation in the lysosomes of certain cell
types, potentially giving rise to clinical pathology (Sun et al.,
2010; Vitner et al., 2010; Zhao and Grabowski, 2002). Nearly
50 distinct lysosomal storage diseases (LSDs) of this type
have been described (Futerman and van Meer, 2004; Parenti
et al., 2013).
The most common LSD is Gaucher’s disease (GD), which is
characterized by the accumulation of the b-glucocerebrosidase
(GCase; encoded by the GBA gene) substrates, glucosylcera-
mide and glucosylsphingosine (Edmunds, 2010; Hruska et al.,
2008). Distinct GCase mutations are subject to varying degrees
of ERAD and thus exhibit different levels of residual lysosomal
GCase activity—generally, the lower the activity, the more se-
vere the GD phenotype (Bendikov-Bar and Horowitz, 2012;
Grace et al., 1994; Ron and Horowitz, 2005; Schmitz et al.,
2005; Schueler et al., 2004). L444P homozygotes exhibiting
extremely low levels of lysosomal GCase activity present with
neuronopathic GD (Grabowski, 1997; Schmitz et al., 2005).
N370S GCase, exhibiting higher residual lysosomal activity,
never presents with any central nervous system symptoms,
even in compound heterozygotes with one null allele (Edmunds,
2010). Instead, these patients present with hepatosplenome-
galy and skeletal disorders, clinical features common to most
GD patients (Beutler and Gelbart, 1993; Tsuji et al., 1988).
Most mutant GCase enzymes, including L444P and N370S,
have been shown to be able to retain their catalytic activity in
the lysosome if they are folded in the ER and subsequently traf-
ficked there, albeit with generally lowered specific activity (Mu
et al., 2008b; Ong et al., 2010; Sawkar et al., 2006; Wang
et al., 2011a). As such, strategies that increase the folded
and functional concentration of mutant GCase in the ER may
prove to be useful for ameliorating GD. Enzyme replacement
therapy with wild-type (WT) GCase harboring an N-glycan
that facilitates lysosomal uptake is generally an effective
treatment; substrate reduction therapy is an alternative for
nonresponders (Parenti et al., 2013). Therapeutic strategies
under development include small molecule pharmacologic7–976, August 14, 2014 ª2014 Elsevier Ltd All rights reserved 967
Figure 1. Identification of GCase Proteostasis Network Compo-
nents
(A) SILAC-immunoprecipitation-MudPIT experimental scheme.
(B) Western blot analysis of immunopurified GCase from WT and L444P
patient-derived fibroblasts. ERdj3 and calnexin coprecipitated with WT and
L444P GCase.
Control experiments were performed with anti-FLAG M2 antibodies. IP,
immunoprecipitation; IB, immunoblot. See also Figure S1.
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ERdj3 Influences Mutant GCase Quality Controlchaperones and enhancers of ER folding capacity (Mu et al.,
2008b; Ong et al., 2010; Sawkar et al., 2006; Wang et al.,
2011a). The former bind to and stabilize mutant GCase in the
ER, increasing the folded concentration that can be trafficked
to the lysosome.
The balance between lysosomal enzyme degradation versus
folding and trafficking (i.e., quality control) is determined by the
stoichiometry of the ER proteostasis network components,
including more than 75 proteins making up numerous inte-
grated or competing proteostatic pathways (Adachi et al.,968 Chemistry & Biology 21, 967–976, August 14, 2014 ª2014 Elsevi2008; Lee et al., 2003; Yamamoto et al., 2007). Thus, we hy-
pothesized that proteostasis network components interacting
with GCase in the ER may play a critical role in facilitating
GCase folding and trafficking, or alternatively in targeting mis-
folded GCase for ERAD. Herein, we immunoprecipitated GCase
and its interacting partners, which were then identified by a
mass-spectrometry-based proteomic approach referred to as
multidimensional protein identification technology (MudPIT)
(Washburn et al., 2001). Cellular biochemical studies on one
particular ER GCase interactor, ERdj3, revealed its importance
in GCase proteostasis decision-making. Depletion of ERdj3
reduced the rate of mutant GCase degradation in patient-
derived fibroblasts, increasing mutant GCase folding, traf-
ficking, and function by redirecting it to the profolding ER
chaperone calnexin. We demonstrated that inhibiting the
mutant GCase-ERdj3 interaction while simultaneously promot-
ing the chaperoning activity of the Ca2+-dependent ER lectin
chaperone calnexin (by diltiazem application) yields a synergis-
tic rescue of L444P GCase lysosomal activity to 50% of WT
GCase activity, which has the potential to be an effective com-
bination therapeutic strategy for GD.
RESULTS
Identification of ER Proteostasis Network Components
that Interact with WT GCase
To identify the proteins that interact with GCase in the ER of
HeLa cells, we utilized stable isotope labeling by amino acids
in cell culture (SILAC) (Ong et al., 2002) together with immuno-
precipitation of endogenous WT GCase (Figure 1A). HeLa cells
were labeled with either ‘‘heavy’’ or ‘‘light’’ isotopes of arginine
and lysine. Prior to lysis of either heavy or light HeLa cells, intra-
cellular protein complexes were crosslinked with the cell-pene-
trable, reversible crosslinker dithiobis(succinimidyl propionate)
(DSP) in an effort to stabilize weak and/or transient interactions.
The 8E4 mouse monoclonal antibody, which recognizes the
extreme C terminus of GCase (Aerts et al., 1986; Barneveld
et al., 1983; Bleijlevens et al., 2008), was covalently coupled to
beads and used for the immunoisolation of WT GCase and its
interacting proteins from the heavy cell lysates. An irrelevant
mouse antibody targeting FLAG, an epitope not present in the
mammalian proteome, was covalently coupled to beads and
used as a negative control in the light population. Proteins
enriched in the heavy population were identified by MudPIT
(Washburn et al., 2001) (Table S1 available online). We focused
on GCase interacting proteins localized to the ER (Table 1), since
these proteins could be important for GCase degradation or
folding and trafficking.
Previous studies have shown that increasing calnexin levels
partially restored the folding, trafficking, and lysosomal function
of L444P GCase (Ong et al., 2010), establishing calnexin as an
important ER chaperone for GCase folding. Calnexin, a mem-
brane-bound lectin chaperone, and its lumenal homolog cal-
reticulin, recognize and bind to Glc1Man9GlcNAc2 glycans on
unfolded glycoproteins. The Ca2+-regulated chaperones cal-
nexin and calreticulin assist the retention and folding of mono-
meric glycoproteins in the ER in collaboration with the protein
disulfide isomerase ERp57 (also known as PDIA3) (Lederkremer,
2009; Ma¨a¨tta¨nen et al., 2010). All three proteostasis networker Ltd All rights reserved
Table 1. ER-Localized Interactors of WT GCase
UniProt ID Gene Symbol Protein Description H/L Ratio Spectral Counts Peptide Number
P04062 GBA glucocerebrosidase 95.51 491 14
P30040 ERP29 endoplasmic reticulum resident protein 29 9.16 15 2
P27824 CANX calnexin 5.05 11 2
P27797 CALR calreticulin 3.61 11 4
P30101 PDIA3 protein disulfide-isomerase A3 (ERp57) 1.95 12 8
Q02809 PLOD1 procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 1.69 3 2
P14625 HSP90B1 endoplasmin (GRP94) 1.55 15 2
Q15084 PDIA6 protein disulfide-isomerase A6 1.55 13 6
P11021 HSPA5 78 kDa glucose-regulated protein (GRP78, BiP) 1.43 174 19
Q9UBS4 DNAJB11 DnaJ homolog subfamily B member 11 (ERdj3) 1.41 5 2
P50454 SERPINH1 Serpin H1 1.4 23 7
See also Table S1.
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interactome approach (Table 1), validating the potential of this
immunoprecipitation and mass-spectrometry-based interac-
tome approach for discovering newGCase proteostasis network
components.
ERdj3 Interacts with WT and Mutant GCase in Patient-
Derived Fibroblasts
The GCase interacting protein identified by our immunoprecipi-
tation and mass spectrometry approach (Table 1) and that we
focused our cellular biochemical confirmation studies on is
DNAJB11 (also known as ERdj3), since its role in GCase proteo-
stasis was unknown. ERdj3 is an ER luminal protein and is one of
the seven ER J-domain-containing Hsp40 cochaperones (Yu
et al., 2000). One established function of ERdj3 is to deliver cli-
ents to BiP, the resident Hsp70 in the ER, and stimulate its
ATPase activity (Kampinga and Craig, 2010; Yu et al., 2000).
ERdj3 is able to interact directly with unfolded client proteins, re-
cruiting them to BiP for ATP-dependent chaperoning in the
Hsp70-Hsp40-NEF (nucleotide exchange factor) folding cycle.
Upon stimulating the ATPase activity of BiP, ERdj3 is released
from the complex (Jin et al., 2009; Shen and Hendershot,
2005). Hsp40s like ERdj3 can also act independently of their cor-
responding Hsp70 (Kampinga and Craig, 2010). For example,
Scj1, a yeast ER Hsp40 similar in domain architecture to
ERdj3, facilitated the degradation of the epithelial sodium chan-
nel independent of BiP (Buck et al., 2010). ERdj3 is established to
be upregulated by activation of the unfolded protein response
(UPR) stress-responsive signaling pathway that controls the pro-
teostasis capacity of the secretory pathway (Shen and Hender-
shot, 2005).
Coimmunoprecipitates of endogenous GCase from WT and
L444P GCase patient-derived fibroblasts subjected to western
blot analysis using antibodies specific for calnexin and ERdj3
(Figure 1B) corroborated our mass spectrometry findings in
HeLa cells, namely that these proteostasis network compo-
nents were GCase interactors. We also observed that G202R
GCase interacted with calnexin and ERdj3 (Figure S1). L444P
and G202R GCase appeared to interact with more calnexin
and ERdj3 in comparison to WT GCase, suggesting that these
misfolding-prone mutants require more assistance from ERChemistry & Biology 21, 96chaperones and cochaperones for their folding and/or
degradation.
ERdj3 Depletion Increases the Lysosomal Activity of
Mutant GCase, but Not WT GCase
We next asked how ERdj3 affects GCase proteostasis by
reducing its cellular concentration using small interfering RNA
(siRNA) in L444P GCase fibroblasts (>90% knockdown at the
transcript level, Figure S2A; >75% knockdown at the protein
level, Figure 2A, middle panel). This resulted in a 1.6-fold
increase in GCase lysosomal activity (20% of WT GCase ac-
tivity), in comparison to the nontargeting (NT) siRNA control
(Figure 2B), without significantly altering cellular viability (resa-
zurin reduction assay; Figure S2B). The glucosylceramide
substrate begins to accumulate when mutant GCase lyso-
somal activity is % 11%–15% of WT GCase activity (Schueler
et al., 2004), suggesting that the increase to 20% is likely to
be sufficient to ameliorate GD symptoms. To investigate if this
increased activity is due to enhanced L444P GCase folding
and trafficking in the ER, we performed endoglycosidase H
(endo H) digestion on L444P GCase cell lysates. Endo H is
able to cleave after asparaginyl-N-acetylglucosamine on gly-
cans that have been linked to GCase in the ER, but it is unable
to cleave this structure once it has been enzymatically pro-
cessed and remodeled into complex oligosaccharides in the
Golgi. Hence, the higher molecular weight endo-H-resistant
band is a reporter for the properly folded and trafficked
(at least to the Golgi) fraction of GCase (Ron and Horowitz,
2005; Sawkar et al., 2006). Knockdown of ERdj3 increased
the endo-H-resistant glycoform band of L444P GCase (Fig-
ure 2A, top panel), indicating that L444P GCase is folded
and trafficked more efficiently upon ERdj3 depletion in the
ER. Furthermore, indirect immunofluorescence microscopy re-
vealed that the knockdown of ERdj3 increased the amount of
detectable L444P GCase, which is normally barely detectable
due to extensive ERAD (Figure 2C, cf. left panels). Importantly,
we observed an enhancement of colocalization of L444P
GCase with the lysosomes as well (Figure 2C, cf. right panels,
artificially colored white).
UsingsiRNA to reduce theERdj3concentration inN370S/V394L
compound heterozygotic GCase fibroblasts (>75% knockdown7–976, August 14, 2014 ª2014 Elsevier Ltd All rights reserved 969
Figure 2. ERdj3 Is a Proteostasis Network
Component for Mutant GCase
(A) Silencing ERdj3 increased the endo-H-resis-
tant glycoform of L444P GCase in fibroblasts. The
quantification of endo-H-resistant L444P GCase
bands is shown below.
(B) Silencing ERdj3 significantly increased L444P
GCase activity in fibroblasts.
(C) Silencing ERdj3 enhanced the lysosomal traf-
ficking of L444P GCase, as assessed by indirect
immunofluorescence microscopy.
(D) Silencing ERdj3 increased the endo-H-resis-
tant glycoform of N370S GCase in fibroblasts. The
quantification of endo-H-resistant N370S GCase
bands is shown below.
(E) Silencing ERdj3 significantly increased N370S
GCase activity in fibroblasts.
The data in (A), (B), (D), and (E) are reported as
mean ± SD (n = 3 for A and D; n = 8 for B and E).
Statistical significance was calculated using a
two-tailed Student’s t test, *p < 0.01. See also
Figures S2 and S3.
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ERdj3 Influences Mutant GCase Quality Controlat the protein level, Figure 2D, middle panel) resulted in a 1.2-fold
increase in GCase activity in comparison to the NT control
(Figure 2E). We also observed a significant increase in the
endo-H-resistant N370S/V394L GCase glycoform band (Fig-
ure 2D, top panel), demonstrating that more of another GCase
mutant (other than L444P) is trafficked to the Golgi and then to970 Chemistry & Biology 21, 967–976, August 14, 2014 ª2014 Elsevier Ltd All rights reservedthe lysosome when the concentration of
ERdj3 is reduced in the ER.
In stark contrast, depleting ERdj3
(>90% knockdown at the transcript
level, Figure S2C; >75% knockdown
at the protein level, Figure S3A, middle
panel) did not alter WT GCase lyso-
somal activity (Figure S3B), or its endo-
H-resistant fraction (Figure S3A, top
panel), even though ERdj3 interacts
with WT GCase (Figures 1B and S1).
We verified that ERdj3 depletion did not
significantly alter mRNA levels of WT
and L444P GBA by using quantitative
RT-PCR (Figures S2A and S2C). More-
over, we did not detect any significant
changes in the mRNA levels of a number
of established UPR markers (CHOP,
spliced XBP1 and GRP78), demon-
strating that stress-responsive signaling
was not induced upon ERdj3 depletion
(Figures S2A and S2C).
ERdj3 Depletion Slows Down the
Degradation of L444P GCase, but
Not WT GCase
To investigate whether ERdj3 knockdown
alters the rate of mutant GCase degrada-
tion, we employed cycloheximide-chase
experiments in L444P GCase fibroblasts.
Following NT or ERdj3 siRNA treatment,the cells were treated with cycloheximide to inhibit general pro-
tein synthesis, then harvested at the indicated time points after
cycloheximide treatment and lysed for western blot analysis (Fig-
ure 3A). L444P GCase typically undergoes extensive degrada-
tion over this time period, as demonstrated in the NT control.
However, when the concentration of ERdj3 was reduced, the
Figure 3. ERdj3 Is Functionally Involved in
the Degradation of L444P GCase, but Not
WT GCase
(A) Silencing ERdj3 significantly reduced the rate of
degradation of L444P GCase in fibroblasts, as
assessed by cycloheximide-chase analysis.
(B) Quantification of L444P GCase bands when NT
(dashed line) and ERdj3 (solid line) siRNA were
applied.
(C) Silencing ERdj3 did not change the rate of
degradation of WT GCase in fibroblasts, as as-
sessed by cycloheximide-chase analysis.
The data in (B) are reported as mean ± SEM (n = 4).
CHX, cycloheximide. See also Figure S4.
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(Figure 3A, quantification shown in Figure 3B). Analogous cyclo-
heximide-chase analysis in WT GCase fibroblasts revealed no
change in the degradation rate of WT GCase when ERdj3 was
silenced (Figure 3C). This suggests that ERdj3 is functionally
involved in the degradation pathway that targets destabilized
mutant GCase, but not WT GCase, for ERAD.
BiP and HYOU1 Do Not Influence the ERdj3-Mediated
Degradation of L444P GCase
Since ERdj3 is the Hsp40 component of the BiP(Hsp70)-Hsp40-
NEF chaperone folding or degradation pathway in the ER, we
wanted to investigate if any of the other components of this
pathway besides ERdj3 could affectmutant GCase proteostasis.
Previous work demonstrated that overexpression of BiP did not
substantially alter the lysosomal activity of L444P GCase (Ong
et al., 2010; Wang et al., 2011a). Knockdown of the major NEF
in the ER, HYOU1, did not increase L444P GCase activity either
(Figure S4A), nor did it increase the endo-H-resistant glycoform
(Figure S4B). Coknockdown of ERdj3 and HYOU1 in L444P
GCase fibroblasts increased GCase activity about 1.4-fold (Fig-
ure S4A) and increased the endo-H-resistant band (Figure S4B)
to levels that were similar to those observed after ERdj3 siRNA
treatment alone. This suggests that BiP and HYOU1 do not
play a significant role in the maintenance of L444P GCase pro-
teostasis, indicating that ERdj3 may be acting independently of
the BiP-Hsp40-NEF folding or degradation cycle.
Reduced Interaction with ERdj3 Directs L444PGCase to
the Calnexin Profolding Pathway
Since depletion of the prodegradation factor ERdj3 in the ER re-
sulted in productive folding and trafficking of L444P GCase, we
hypothesized that ERdj3 competes with calnexin, an ER chap-
erone known to be important for GCase binding and folding
(Ong et al., 2010). When the cellular concentration of ERdj3
was reduced, more calnexin was bound to immunoprecipitated
L444P GCase (Figure 4A), indicating that L444P GCase was
indeed being directed toward the calnexin profolding pathway.Chemistry & Biology 21, 967–976, August 14, 2014In contrast, there was no significant
change in the amount of calnexin bound
to WT GCase when ERdj3 was silenced
in WT GCase fibroblasts (Figure 4B),
consistent with the finding that ERdj3is not functionally involved in the degradation of WT GCase
(Figures 3C and S3).
ERdj3 Depletion Together with Diltiazem Treatment
Synergistically Enhances L444P GCase Folding,
Trafficking, and Lysosomal Activity
Diltiazem treatment is established to improve L444P GCase
proteostasis in patient-derived fibroblasts by inhibiting the ER
ryanodine receptor Ca2+ efflux channels, thereby increasing ER
Ca2+ levels and enhancing the chaperoning activity of calnexin,
a Ca2+-dependent chaperone (Mu et al., 2008a; Ong et al.,
2010). We hypothesized that since more L444P GCase
was directed toward the calnexin profolding pathway in the
absence of ERdj3, increasing the chaperoning activity of cal-
nexin (by application of diltiazem) could further enhance the
folding, trafficking, and lysosomal function of L444P GCase.
Diltiazem and ERdj3 siRNA were coadministered to L444P
GCase fibroblasts over a 7-day period (Figure 4C). Consistent
with previous results (Ong et al., 2010; Wang et al., 2011b), dil-
tiazem treatment (10 mM) alone increased the activity of L444P
GCase by 1.5-fold (or a 50 unit increase). Interestingly, applica-
tion of ERdj3 siRNA over a 7-day period dramatically improved
the activity of L444P GCase by 2.9-fold (or a 190 unit increase),
as compared to the 1.6-fold increase observed when siRNA
was applied over 4 days. This demonstrates that prolonged
inhibition of the L444P GCase-ERdj3 interaction is beneficial
for L444P GCase folding and trafficking and is consistent with
ERdj3 being a long-lived protein (protein half-life = 98 hr;
mRNA half-life = 20 hr) (Schwanha¨usser et al., 2011). Figure S5A
depicts the linear increase in L444P GCase activity from 4 to
7 days when treated with ERdj3 siRNA. When diltiazem and
ERdj3 siRNA were coapplied using the regimen shown, we
observed a 4.1-fold increase (or a 310 unit increase) in L444P
GCase activity (to approximately 50% of WT GCase activity;
Figure 4C) after 7 days of treatment. This is significantly more
than the 3.4-fold or 240 unit sum of either treatment alone,
revealing a synergistic enhancement of L444P GCase activity
(Figure 4C).ª2014 Elsevier Ltd All rights reserved 971
Figure 4. Simultaneous Inhibition of the GCase-ERdj3 Interaction
and Enhancement of the Chaperoning Activity of Calnexin Exhibits
Synergy in L444P GCase Fibroblasts
(A) Silencing ERdj3 enhanced the interaction between L444P GCase and
calnexin in fibroblasts.
(B) Silencing ERdj3 did not affect the interaction between WT GCase and
calnexin in fibroblasts. IP, immunoprecipitation; IB, immunoblot.
(C) Coapplication of diltiazem and ERdj3 siRNA synergistically enhanced
L444P GCase lysosomal activity.
The data in (C) are reported as mean ± SD (n = 8). DTZ, diltiazem. See also
Figure S5.
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fying that coadministration of diltiazem and ERdj3 siRNA signif-
icantly rescued the folding, trafficking, and lysosomal function of
L444P GCase. We did not observe any increase in GBA tran-
script levels in any of the experiments depicted in Figure 4C,
nor did we observe induction of the UPR based on quantitative
RT-PCR (Figure S5C). Notably, cell viability was not reduced,
as measured by the resazurin reduction assay (Figure S5D).
DISCUSSION
Our immunoprecipitation and mass spectrometry approach to
discover new GCase interactors and/or proteostasis network972 Chemistry & Biology 21, 967–976, August 14, 2014 ª2014 Elsevicomponents has led to the identification and characterization
of ERdj3. Reducing the concentration of ERdj3 in patient-derived
fibroblasts diminishes the rate of mutant GCase degradation and
enhances the folding and trafficking of mutant GCase, but not
WT GCase, despite the fact that ERdj3 interacts with both. In
fact, the extent of the folding, trafficking, and lysosomal activity
enhancement appears to be dependent on the stability of
the mutant GCase—the more unstable the GCase variant, the
greater the activity enhancement observed. The L444P GCase
variant is more destabilized at pH 7 in the ER compared to the
N370S GCase mutant (Edmunds, 2010; Sawkar et al., 2006;
Schmitz et al., 2005) and hence is degraded more extensively
by ERAD (Ron andHorowitz, 2005).WTGCase is processed nor-
mally in the ER (Bendikov-Bar and Horowitz, 2012; Ron and Hor-
owitz, 2005). Inhibiting ERAD through ERdj3 depletion resulted
in greater enhancement of L444P GCase proteostasis than
N370S GCase proteostasis—no WT GCase enhancement was
observed. When these data are considered together with the
observation that significantly more ERdj3 binds tomutant GCase
than to WT GCase, we hypothesize that ERdj3 is able to discrim-
inate between GCase sequences based on their extent of desta-
bilization, consistent with ERdj30s established ability to bind
to unfolded client proteins in the ER (Jin et al., 2009; Shen and
Hendershot, 2005).
It appears that unfolded mutant GCase partitions between
a calnexin-assisted folding pathway and an ERdj3-mediated
ERAD pathway early in the secretory pathway (Figure 5). In our
proposed model, ERdj3 and calnexin compete for the unfolded
mutant GCase enzyme in the ER, resulting in its degradation
or folding, respectively. Reducing the cellular concentration of
ERdj3 decreases its interaction with misfolded mutant GCase,
allowing profolding components like calnexin (and perhaps other
components of the proteostasis network) to compete for the
unfolded enzyme, eventually resulting in its folding and sub-
sequent trafficking to the lysosome as a functional GCase
enzyme. To further support this hypothesis, we demonstrated
that enhancement of the Ca2+-regulated chaperoning activity of
the calnexin pathway via diltiazem treatment along with simulta-
neous inhibition of the ERdj3-GCase interaction synergistically
rescued L444P GCase proteostasis, increasing L444P activity
to 50% of WT GCase lysosomal activity. This is significantly
above the GCase activity threshold at which the substrate gluco-
sylceramide begins to accumulate in the cell (%11%–15%ofWT
GCase activity) (Schueler et al., 2004). Despite a reduced associ-
ation of WT GCase with ERdj3, we did not observe an enhanced
interaction with calnexin, suggesting that reducing the binding
of ERdj3 to WT GCase does not have a functional outcome.
Maintaining Ca2+ homeostasis in the ER is of particular impor-
tance, since the accumulation of glucosylceramide has been
shown to cause extensive Ca2+ efflux through the ryanodine re-
ceptors in GD neurons (Korkotian et al., 1999; Lloyd-Evans et al.,
2003; Pelled et al., 2005). Diltiazem is an FDA-approved L-type
Ca2+ channel blocker drug for the treatment of hypertension
(Hockerman et al., 1997; Massie et al., 1984, 1987). It also re-
stores ER Ca2+ homeostasis through the inhibition of Ca2+ efflux
via the ryanodine receptors (Shoshan-Barmatz et al., 1991),
potentially reversing the effect of glucosylceramide accumula-
tion. Notably, this increase in ER Ca2+ levels has been previously
shown to enhance the calnexin-mutant GCase interactioner Ltd All rights reserved
Figure 5. ERdj3 Is a Degradation versus
Folding Partitioning Factor for Mutant
GCase
In our proposed model, ERdj3 and calnexin
compete for the unfolded mutant GCase enzyme
in the ER, resulting in its degradation or folding,
respectively. When the ERdj3-mediated ERAD
pathway is inhibited, mutant GCase partitions into
the calnexin folding cycle, which can be further
enhanced by diltiazem treatment, thereby leading
to a synergistic rescue of mutant GCase folding,
trafficking, and lysosomal activity.
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ERdj3 Influences Mutant GCase Quality Controlresulting in improved L444P GCase proteostasis (Ong et al.,
2010), suggesting that diltiazem treatment functions, at least
partially, by increasing the calnexin chaperoning of mutant
GCase. Diltiazem treatment also significantly increased GCase
lysosomal activity in a number of mouse skin fibroblast lines
derived from individual GCase point-mutated homozygous
mice (Sun et al., 2009). Despite mimicking the low residual
GCase activity seen in human patient tissues, these mouse
models do not recapitulate the phenotypic abnormalities of hu-
man patients (Farfel-Becker et al., 2011; Xu et al., 2003). While
the effects of diltiazem in vivo appeared to be minimal when
dosed in these GD mouse models (Sun et al., 2009), it is clear
from our work that the effect of diltiazem will likely be more pro-
nounced when the ERdj3-mutant GCase interaction is also abro-
gated by ERdj3 depletion, since this inhibition of ERAD increases
the pool of available mutant GCase in the ER, which is then
redirected toward the Ca2+-enhanced calnexin folding pathway
(Figure 5).
In summary, our study strongly indicates that inhibition of the
mutant GCase ERAD pathway by depleting ERdj3 while simulta-
neously enhancing the profolding calnexin pathway via diltiazem
treatment markedly tilts the balance in favor of the folding and
trafficking of mutant GCase versus degradation. Since we did
not observe any UPR induction or diminished cell viability with
this regimen, this represents a promising therapeutic strategy
for ameliorating GD, especially considering that there are a
plethora of regulatory-agency-approved drugs with outstanding
safety records that elevate ER Ca2+ levels.
SIGNIFICANCE
The abovementioned results show that the proteostasis
network components that interact with GCase in the ER are
involved in making important quality control decisions,
namely, decisions regarding degradation versus folding andChemistry & Biology 21, 967–976, August 14, 2014trafficking to the lysosome. In partic-
ular, depletion of ERdj3 significantly
diminished the rate of mutant GCase
degradation, thereby enhancing its
folding, trafficking, and lysosomal
function. Furthermore, inhibition of
the ERdj3-mediated ERAD pathway
along with simultaneous enhancement
of the profolding calnexin pathway via
diltiazem treatment synergistically res-cuesmutant GCase lysosomal activity to levels thought to be
more than sufficient to ameliorate GD. These results suggest
that depleting ERdj3 in combination with drugs that enhance
ERCa2+ levels (e.g., diltiazem) merits further investigation as
a strategy for neuronopathic GD patients that cannot be
treated by enzyme replacement therapy because the recom-
binant protein does not cross the blood-brain barrier.
EXPERIMENTAL PROCEDURES
Reagents
4-Methylumbelliferyl b-D-glucopyranoside (MUG) was from Sigma (St. Louis,
MO). Conduritol B epoxide (CBE) was from Toronto Research Chemicals
(Downsview, ON, Canada). Diltiazem hydrochloride was from Tocris Biosci-
ence (Ellisville, MO). Cell culture media were purchased from Gibco (Grand
Island, NY).
Cell Cultures
Primary skin fibroblast cultures were established from Gaucher’s patients ho-
mozygous for the G202R (c.721G > A) mutation and were kindly provided by
Dr. K.P. Zimmer (Children’s Hospital of the University of Munster, Munster).
An apparently normal fibroblast cell line (GM00498), the Gaucher’s disease
fibroblast cell line homozygous for the L444P (c.1448T > C) mutation
(GM08760), and the Gaucher’s disease fibroblast cell line heterozygous for
the N370S (c.1226A > G) and V394L (c.1297G > T) mutations (GM01607)
were from Coriell Cell Repositories (Camden, NJ). Fibroblasts were grown
in a minimal essential medium with Earle’s salts, 10% heat-inactivated fetal
bovine serum, and 1% glutamine Pen-Strep at 37C in 5% CO2. The cell
medium was replenished every 3 or 4 days and monolayers were passaged
with TrypLE Express upon reaching confluency.
SILAC and Immunoprecipitation of GCase
Two populations of HeLa cells were cultured in SILAC Dulbecco’s modified
Eagle’s medium media containing 10% dialyzed fetal bovine serum and 1%
Pen-Strep (Cambridge Isotope Laboratories, Andover, MA). The light medium
was supplemented with unlabeled L-lysine and L-arginine, and the heavy
medium was supplemented with isotopic-labeled L-lysine and L-arginine
(13C6-lysine and
13C6
15N4-arginine). After at least five passages, the light
and heavy HeLa cell populations were harvested and washed once withª2014 Elsevier Ltd All rights reserved 973
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ERdj3 Influences Mutant GCase Quality ControlDulbecco’s phosphate buffered saline (DPBS). Each population was resus-
pended in DPBS and crosslinkedwith 1mMDSP for 30min at RT. The reaction
was quenched with 100 mM Tris (pH 8) for 15 min at RT. The cells were lysed
with a radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 7.5],
150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1%
SDS) supplemented with a complete protease inhibitor cocktail (Roche) on
ice, clarified by centrifugation, and precleared with GammaBind G Sepharose
beads (GE Healthcare) for 1.5 hr at 4C. The heavy lysate was incubated
with 8E4 antibody-coupled beads, and the light lysate was incubated with
FLAG M2 antibody-coupled beads overnight at 4C. See the Supplemental
Experimental Procedures for the coupling of antibodies to GammaBind
G Sepharose beads. After overnight incubation with lysates at 4C, the beads
were pelleted and washed three times with RIPA buffer. The beads were com-
bined pairwise and eluted in 2% SDS, 50 mM Tris (pH 7.5) for 10 min at 100C.
GCase eluates were analyzed by mass spectrometry; see the Supplemental
Experimental Procedures for the detailed method.
Enzyme Activity Assay
The intact cell GCase activity assay for GD fibroblasts using the MUG sub-
strate has been described previously (Mu et al., 2008b). Each reported data
point was evaluated at least in triplicate in each plate and on three different
days. See the Supplemental Experimental Procedures for the detailedmethod.
Western Blot Analysis
Cells were lysed in complete lysis-M buffer (Roche) containing a complete
protease inhibitor cocktail (Roche). The total protein concentration was deter-
mined using the Micro BCA assay reagent (Pierce). Company specifications
were followed for treatment with endo H (New England Biolabs). Aliquots of
cell lysates were separated in an 8% or 10% SDS-PAGE gel, and western
blot analysis was performed using appropriate antibodies. Details of anti-
bodies used are given in the Supplemental Experimental Procedures.
Indirect Immunofluorescence Microscopy
Immunofluorescence was performed as previously described (Mu et al.,
2008b). The experiments were performed three times and similar results
were obtained. See the Supplemental Experimental Procedures for the
detailed method.
Transfection of siRNA
Patient-derived GD fibroblasts were transfected with siRNA as previously
described (Ong et al., 2013). Briefly, fibroblasts were seeded in 6-well plates
at approximately 2 3 105 cells per well and incubated at 37C overnight to
reach 70%–80% confluency before transient transfection using HiPerfect
Transfection Reagent (QIAGEN), according to the manufacturer’s protocol.
The siRNA duplexes were from Dharmacon: DNAJB11/ERdj3 (J-015861-
09), HYOU1 (J-003678-09), and nontargeting siRNA (D-001810-01-20) as
control.
Quantitative RT-PCR
Relative expression levels of target genes were measured by quantitative RT-
PCR using the forward and reverse primers for the genes analyzed (Table S2).
The total RNA was extracted from fibroblasts by using RNeasy Mini Kit
(QIAGEN #74104). The cDNA was synthesized from 500 ng of total RNA using
QuantiTect Reverse Transcription Kit (QIAGEN #205311). Quantitative PCR
reactions (6 min at 95C, then 45 cycles of 15 s at 95C and 60 s at 60C)
were performed using cDNA, FastStart Universal SYBRGreenMaster (Roche),
and corresponding primers (Table S2) in an ABI 7900HT Fast Real Time
PCR machine (Applied Biosystems) and analyzed using DataAssist software
(Applied Biosystems). Each data point was evaluated in triplicate and
measured three times.
Cycloheximide-Chase Assay
Fibroblasts were seeded in 6-well plates at approximately 2 3 105 cells per
well and incubated at 37C overnight. Fibroblasts were treated with transfec-
tion complexes as indicated. To arrest protein translation, 50 mg/mL cyclo-
heximide (Chem Service) was added to each well. Cells were then chased
for the indicated period of time, harvested, and lysed for western blot
analysis.974 Chemistry & Biology 21, 967–976, August 14, 2014 ª2014 ElseviStatistical Analysis
All data are presented as mean ± SEM or mean ± SD as stated, and any sta-
tistical significance was calculated using a two-tailed Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2014.06.008.
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